HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Collins, P. L. Articles by Murphy, B. R. Search for Related Content PubMed PubMed Citation Articles by Collins, P. L. Articles by Murphy, B. R.

New Generation Live Vaccines against Human Respiratory Syncytial Virus Designed by Reverse Genetics

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland

Correspondence and requests for reprints should be addressed to Peter L. Collins, Building 50, Room 6503, 50 South Dr. MSC 8007, Bethesda, MD 20892-8007. E-mail: pcollins{at}niaid.nih.gov

Development of a live pediatric vaccine against human respiratory syncytial virus (RSV) is complicated by the need to immunize young infants and the difficulty in balancing attenuation and immunogenicity. The ability to introduce desired mutations into infectious virus by reverse genetics provides a method for identifying and designing highly defined attenuating mutations. These can be introduced in combinations as desired to achieve gradations of attenuation. Attenuation is based on several strategies: multiple independent temperature-sensitive point mutations in the polymerase, a temperature-sensitive point mutation in a transcription signal, a set of non–temperature-sensitive mutations involving several genes, deletion of a viral RNA synthesis regulatory protein, and deletion of viral IFN /ß antagonists. The genetic stability of the live vaccine can be increased by judicious choice of mutations. The virus also can be engineered to increase the level of expression of the protective antigens. Protective antigens from antigenically distinct RSV strains can be added or swapped to increase the breadth of coverage. Alternatively, the major RSV protective antigens can be expressed from transcription units added to an attenuated parainfluenza vaccine virus, making a bivalent vaccine. This would obviate the difficulties inherent in the fragility and inefficient in vitro growth of RSV, simplifying vaccine design and use.

Key Words: paramyxoviruses • pediatric vaccines • recombinant DNA vaccines • respiratory infections • vaccine development

This article has been cited by other articles:

				S. Kwilas, R. M. Liesman, L. Zhang, E. Walsh, R. J. Pickles, and M. E. Peeples Respiratory Syncytial Virus Grown in Vero Cells Contains a Truncated Attachment Protein That Alters Its Infectivity and Dependence on Glycosaminoglycans J. Virol., October 15, 2009; 83(20): 10710 - 10718. [Abstract] [Full Text] [PDF]

				U. J. Buchholz, J. M. Ward, E. W. Lamirande, B. Heinze, C. D. Krempl, and P. L. Collins Deletion of Nonstructural Proteins NS1 and NS2 from Pneumonia Virus of Mice Attenuates Viral Replication and Reduces Pulmonary Cytokine Expression and Disease J. Virol., February 15, 2009; 83(4): 1969 - 1980. [Abstract] [Full Text] [PDF]

				C. B. Hall, G. A. Weinberg, M. K. Iwane, A. K. Blumkin, K. M. Edwards, M. A. Staat, P. Auinger, M. R. Griffin, K. A. Poehling, D. Erdman, et al. The Burden of Respiratory Syncytial Virus Infection in Young Children N. Engl. J. Med., February 5, 2009; 360(6): 588 - 598. [Abstract] [Full Text] [PDF]

				V. G. Bhoj, Q. Sun, E. J. Bhoj, C. Somers, X. Chen, J.-P. Torres, A. Mejias, A. M. Gomez, H. Jafri, O. Ramilo, et al. MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus PNAS, September 16, 2008; 105(37): 14046 - 14051. [Abstract] [Full Text] [PDF]

				J. Eckardt-Michel, M. Lorek, D. Baxmann, T. Grunwald, G. M. Keil, and G. Zimmer The Fusion Protein of Respiratory Syncytial Virus Triggers p53-Dependent Apoptosis J. Virol., April 1, 2008; 82(7): 3236 - 3249. [Abstract] [Full Text] [PDF]

				P. L. Collins and B. S. Graham Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis J. Virol., March 1, 2008; 82(5): 2040 - 2055. [Full Text] [PDF]

				D. Silin, O. Lyubomska, M. Ludlow, W. P. Duprex, and B. K. Rima Development of a Challenge-Protective Vaccine Concept by Modification of the Viral RNA-Dependent RNA Polymerase of Canine Distemper Virus J. Virol., December 15, 2007; 81(24): 13649 - 13658. [Abstract] [Full Text] [PDF]

				J. V. Williams, Z. Chen, G. Cseke, D. W. Wright, C. J. Keefer, S. J. Tollefson, A. Hessell, A. Podsiad, B. E. Shepherd, P. P. Sanna, et al. A Recombinant Human Monoclonal Antibody to Human Metapneumovirus Fusion Protein That Neutralizes Virus In Vitro and Is Effective Therapeutically In Vivo J. Virol., August 1, 2007; 81(15): 8315 - 8324. [Abstract] [Full Text] [PDF]

				D. Govindarajan, U. J. Buchholz, and S. K. Samal Recovery of Avian Metapneumovirus Subgroup C from cDNA: Cross-Recognition of Avian and Human Metapneumovirus Support Proteins. J. Virol., June 1, 2006; 80(12): 5790 - 5797. [Abstract] [Full Text] [PDF]